Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.46 |
| ▸ | AKT2 | P31751 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1382336 | 0.83 | NPC1 (0.58) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL3733195 | 0.83 | NPC1 (0.58) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL6246765 | 0.83 | KMT2A (0.56) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL1516264 | 0.81 | NPC1 (0.45) | MEN1NPC1RAB9AKMT2AATM | |
| Acrylamide SCHEMBL11697571 | 0.80 | MEN1 (0.48) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL4417037 | 0.77 | P2RX7 (0.44) | ALDH1A1KDM4EHPGDHSD17B10CES1 | |
| SCHEMBL1515297 | 0.76 | L3MBTL1 (0.54) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL1515148 | 0.76 | NPC1 (0.48) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL3909699 | 0.76 | MEN1 (0.48) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL3092743 | 0.76 | NPC1 (0.48) | MEN1NPC1RAB9AKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | claimed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | claimed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | claimed |
| EP-3490986-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2019-06-05 | — | — | EP | claimed |
| WO-2018019929-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-02-01 | — | — | WO | claimed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | claimed |
| EP-2771327-B1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | claimed |
| EP-2038264-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | claimed |
| US-9403808-B2 | Pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-08-02 | — | — | US | claimed |
| WO-2007018465-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| US-20060223798-A1 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-10-05 | — | — | US | claimed |
| WO-2006049880-A1 | TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | claimed |
| US-20060089378-A1 | Tetrahydro-pyridinyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-27 | — | — | US | claimed |
| CN-1246432-C | Ligand and complex for catlytically bleaching substrate | UNILEVER NV (NL) | 2006-03-22 | — | — | CN | claimed |
| CN-1481435-A | Ligand and complex for catlytically bleaching substrate | — | 2004-03-10 | — | — | CN | claimed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | claimed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | claimed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-0761654-A1 | Isoxazole- and isothiazole-5-carboxamide derivatives, their preparation and their use as herbicides | American Cyanamid Company (US) | 1997-03-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223798-A1 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | CNR1, CNR2, GPR18 | MEN1 4352/4885NPC1 352/4885RAB9A 1510/4885 |
| US-20060089378-A1 | Tetrahydro-pyridinyl pyrazole cannabinoid modulators | CNR2, CNR1, GPR18 | MEN1 3273/4885NPC1 440/4885RAB9A 1137/4885 |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | MEN1 4036/4885NPC1 70/4885RAB9A 1539/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | MEN1 4254/4885NPC1 1342/4885RAB9A 628/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | MEN1 4254/4885NPC1 1342/4885RAB9A 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.